Sage Therapeutics and Biogen Announce the Phase 3 CORAL Stud

Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD

Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
biogen.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biogen.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Japan , Cambridge , Cambridgeshire , United Kingdom , Michigan , United States , Charles Weissmann , Walter Gilbert , Heinz Schaller , Sagar Parikh , Ashleigh Koss , Priya Singhal , Mike Hencke , Maureenl Suda , Helen Rubinstein , Barry Greene , Kenneth Murray , Linkedin , Twitter , Regulatory Sciences , Psychiatry Sciences , Biogen Inc , Nasdaq , University Of Michigan , Exchange Commission , Sage Therapeutics Inc , Youtube , Facebook , Sage Therapeutics , Hamilton Rating Scale , Chief Executive Officer , New Drug Application , Global Safety , Interim Head , Clinical Neuroscience , Summary Results , Hamilton Depression Rating Scale , Least Squares , Each Time Point , Blinded Treatment Period , Key Secondary Endpoint , Columbia Suicide Severity Rating Scale , Major Depressive Disorder , Sir Kenneth Murray , Nobel Prize , Healthy Lives , Private Securities Litigation Reform Act , Quarterly Report ,